

Synthetic studies on sugar-fused erinacines

Ayato Sato,^a Tomoya Masuda,^a Hirokazu Arimoto^{*a,b,c} and Daisuke Uemura^{a,b}

^a Department of Chemistry, Graduate School of Science, Nagoya University, Chikusa, Nagoya, 464-8602, Japan. E-mail: arimoto@biochem.tohoku.ac.jp; Fax: +81 52 789 5041; Tel: +81 52 789 2479

^b Institute for Advanced Research, Nagoya University, Chikusa, Nagoya, 464-8602, Japan

^c PRESTO, JST, Chikusa, Nagoya, 464-8602, Japan

Received 8th March 2005, Accepted 20th April 2005

First published as an Advance Article on the web 4th May 2005

Samarium-mediated 7-endo-trig radical cyclization afforded excellent stereocontrol of the four contiguous asymmetric centers present in the 6-7-6 tricyclic cores of the (sugar-fused) erinacines E, F, and G.

The erinacines were isolated by Kawagishi from myceria of the fungus *Hericium erinaceum*, as potent stimulators of nerve growth factor (NGF) synthesis.¹ Erinacines E **1**, F **2**, and G **3** share carbocyclic E-rings that are not seen in other cyathan diterpenes,³ thus constituting a unique subgroup among the erinacine family (Fig. 1). These E-rings are probably biosynthesized by fusion of a sugar unit with a diterpenoid aglycon (cyathan skeleton). In 1998, Saito *et al.* investigated erinacine E **1** from the fermentation broth of a basidiomycete (*Hericium ramosum* CL24240), and that it had κ -opioid receptor agonist activity.⁴ Despite their intriguing structure and biological activities, no synthetic studies have focused on the substructural family containing erinacines E, F, and G.^{5,6} We report here the efficient construction of the common 6-7-6 tricyclic core **4**. A notable challenge in this synthesis was the construction of the central

7-membered ring, which possesses four contiguous asymmetric centers.

Our synthetic plan is outlined in Scheme 1. Disconnection at the C13–C14 bond of **4** gives the ald-enone **5**, a key precursor in our study. We chose samarium-mediated radical cyclization for this transformation.^{7,8} Only a few examples of 7-endo-trig radical cyclization have been reported,⁹ but we predicted that its mild reaction conditions would be suitable for polyfunctionalized target molecules.

Our synthesis commenced with chemoselective reduction of **6** (96% ee) (Scheme 2).¹⁰ Swern oxidation of the resulting primary alcohol gave an aldehyde with a *syn* relative configuration. Treatment of the *syn*-aldehyde with DBU afforded an equilibrium mixture of aldehydes (*syn* : *anti* = 1 : 1). The desired *anti*-isomer **7** was isolated, and the recovered *syn*-isomer was treated again. After two cycles of these processes, **7** was obtained in 70% yield. The *anti*-isomer **7** was then converted into homologated aldehyde **8** by a Wittig reaction and hydrolysis of the resulting enol ether without any epimerization at C-5. The installation of 2-cyclohexen-1-one with the Morita–Baylis–Hillman reaction¹¹ proved to be more difficult than anticipated. Numerous reaction






Fig. 1 Sugar-fused erinacines.




Scheme 2 Reagents and conditions: a) i) *t*-BuOCOCi, Et₃N, Et₂O; ii) NaBH₄, THF, 87% (2 steps); b) (COCl)₂, DMSO; Et₃N, CH₂Cl₂, 90%; c) DBU, MeOH; d) separation of isomers, 70% of **7** after 2 cycles; e) *t*-BuOK, MeOCH₂PPh₃Cl, toluene, 68%; f) TFA, THF–H₂O (1 : 1), 94%; g) 2-cyclohexen-1-one, DBU, Et₂O–MeOH (9 : 1), 47% for **9a** and 47% for **9b**; h) TBSOTf, 2,6-lutidine, CH₂Cl₂, 78% from **9a** and 82% from **9b**; i) DIBAL, toluene; j) TPAP, NMO, 4 Å MS, CH₂Cl₂, 66% for **5a** and 81% for **5b**.



Scheme 1 Synthetic plan.


systems were surveyed, and finally, aldehyde **8** and 2-cyclohexen-1-one were treated with DBU in Et₂O–MeOH, and the desired product **9** was obtained in 94% yield. The use of MeOH as a co-solvent was found to be essential, with **9** being obtained in poor yield (<30%) in the absence of MeOH. Diastereomeric secondary alcohols **9a** and **9b**¹² were protected as their *tert*-butyldimethylsilyl ethers. Reduction of the *tert*-butyl ester and the enone moiety, followed by oxidation of the resulting diol with TPAP, gave ald-enones **5a** and **5b**, respectively.

With the key precursor **5** in hand, we attempted the samarium-mediated radical cyclization. With ald-enone **5b** as a starting material, the cyclization reaction proceeded smoothly to give **4** in 86% yield as a single diastereomer. Structural assignment of cycloadduct **4** was initially obtained through ¹H-NMR, ¹³C-NMR, COSY, HMBC, and HOHAHA experiments, and these spectra showed that **4** has the 6-7-6 tricyclic core as a platform. The NOE correlations between H-12 and Me-16, and H-12 and H-14 indicated that both H-12 and H-14 protons are oriented in an *α* configuration. The 12, 13-*trans* stereochemistry was assigned on the basis of the coupling constant ($J_{12,13} = 12.8$ Hz). These experiments revealed that compound **4** has the correct stereochemistry on four contiguous carbons, C-5, C-6, C-14, and C-13.¹³ Finally, desilylation of **4** afforded a diol, and acetylation and subsequent elimination of the resulting acetate afforded **10** with the same configuration of functional groups as in erinacines E, F, and G (Scheme 3).




Scheme 3 Reagents and conditions: l) SmI₂ (20 eq.), THF–*t*-BuOH, (100 : 1), 0 °C, 2 h, 86%; m) TBAF, AcOH, THF, 67%; n) Ac₂O, DBU, CH₂Cl₂, 96%.

Unexpectedly, the radical cyclization with ald-enone **5a** failed under the conditions described above. The products were inseparable mixtures of **13** and **14** (*ca.* 1 : 1). When a Lewis-basic additive, HMPA, was added to increase the reduction potential,¹⁴ the sole product was **14** in 76% yield. The stereochemistry of the newly formed chiral centers at C-15 in **13** and **14** was not determined (Scheme 4).



Scheme 4 Reagents and conditions: o) SmI₂ (20 eq.), THF–*t*-BuOH (100 : 1), 0 °C, 3.5 h, 76%

The stereochemical outcomes of the 7-*endo-trig* radical cyclization of **5b** might be explained as follows (Scheme 5). The cyclization from intermediate **I** leads to a *cis* arrangement between the newly formed hydroxy group at C-14 and the hydrogen atom at C-13. This process is preferable to approach **III**, which suffers from repulsion between Me-16, H-10, and H-13. The resulting samarium enolate is protonated stereoselectively to afford thermodynamically more stable **4** as a single isomer.



Scheme 5


In summary, we have succeeded in constructing the central 6-7-6 core ring system that exists in sugar-fused erinacines by an efficient samarium-mediated radical cyclization. These synthetic studies should constitute a firm basis for synthesis of the sugar-fused erinacine subfamily. Further efforts toward the synthesis of erinacine E will be reported in due course.

This research was supported in part by the Sasagawa Scientific Research Grant, a Grant-in-Aid for Scientific Research, and the 21st century COE program (Establishment of COE on Material Science) from the Ministry of Education, Science, Sports, and Culture (MEXT), Japan.

Notes and references

- H. Kawagishi, A. Shimada, R. Shirai, K. Okamoto, F. Ojima, H. Sakamoto, Y. Ishiguro and S. Furukawa, *Tetrahedron Lett.*, 1994, **35**, 1569.
- H. Kawagishi, A. Shimada, S. Hosokawa, H. Mori, H. Sakamoto, Y. Ishiguro, S. Sakemi, S. Watanabe, J. Bordner, N. Kojima and S. Furukawa, *Tetrahedron Lett.*, 1996, **37**, 7399.
- W. A. Ayer and H. Taube, *Tetrahedron Lett.*, 1972, **13**, 1917; H. Shibata, A. Irie and Y. Morita, *Biosci., Biotechnol., Biochem.*, 1998, **62**, 2450; T. Ohta, T. Kita, N. Kobayashi, Y. Obara, N. Nakahata, Y. Ohizumi, Y. Tanaka and Y. Oshima, *Tetrahedron Lett.*, 1998, **39**, 6229.
- T. Saito, F. Aoki, H. Hirai, T. Inagaki, Y. Matsunaga, T. Sakakibara, S. Sakemi, Y. Suzuki, S. Watanabe, O. Suga, T. Sujaku, A. A. Smogowicz, S. J. Truesdell, J. W. Wong, A. Nagahisa and N. Kojima, *J. Antibiot.*, 1998, **51**, 983.
- B. B. Snider, N. H. Ho, S. V. O'Neil and B. M. Foxman, *J. Am. Chem. Soc.*, 1996, **118**, 7644; M. Tori, N. Toyoda and M. Sono, *J. Org. Chem.*, 1998, **63**, 306; D. E. Ward, Y. Gai and Q. Qiao, *Org. Lett.*, 2000, **2**, 2125; E. Piers, M. Gilbert and K. L. Cook, *Org. Lett.*, 2000,

- 2, 1407; M. Takano, A. Umino and M. Nakada, *Org. Lett.*, 2004, **6**, 4897.
- 6 E. Piers and K. L. Cook, *Chem. Commun.*, 1996, 1879; P. Magnus and L. Shen, *Tetrahedron*, 1999, **55**, 3553; D. L. Wright, C. R. Whitehead, E. H. Sessions, I. Ghiviriga and D. A. Frey, *Org. Lett.*, 1999, **1**, 1535; K. Takeda, D. Nakane and M. Takeda, *Org. Lett.*, 2000, **2**, 1903; P. A. Wender, F. C. Bi, M. A. Brodney and F. Gosselin, *Org. Lett.*, 2001, **3**, 2105; C. Thominaux, A. Chiaroni and D. Desmaele, *Tetrahedron Lett.*, 2002, **43**, 4107.
- 7 For a review, see: H. B. Kagan, *Tetrahedron*, 2003, **59**, 10351; D. J. Edmonds, D. Johnston and D. J. Procter, *Chem. Rev.*, 2004, **104**, 3371.
- 8 Recently, Tori *et. al.* and Suzuki *et. al.* independently reported 6-*endo-trig* cyclization: M. Sono, Y. Nakashiba, K. Nakashima and M. Tori, *J. Org. Chem.*, 2000, **65**, 3099; H. Hagiwara, H. Sakai, T. Uchiyama, Y. Ito, N. Morita, T. Hoshi, T. Suzuki and M. Ando, *J. Chem. Soc., Perkin Trans. 1*, 2002, 583.
- 9 M. Ohtsuka, Y. Takekawa and K. Shishido, *Tetrahedron Lett.*, 1998, **39**, 5803.
- 10 H. J. Gais, K. L. Lukas, W. A. Ball, S. Braun and H. J. Lindner, *Leibigs Ann. Chem.*, 1986, 687; M. Shimada, S. Kobayashi and M. Ohno, *Tetrahedron Lett.*, 1988, **29**, 6961.
- 11 K. Morita, Z. Suzuki and H. Hirose, *Bull. Chem. Soc. Jpn.*, 1968, **41**, 2815; A. B. Baylis and M. E. D. Hillman, *Ger. Pat.* 2155113 C. A., 1972, vol. 77, p. 3417.
- 12 The configuration at C-11 in **9a** and **9b** was confirmed by converting them to lactones **12a** and **12b**, respectively; a NOE was observed between H-11 and Me-16 in **12a**.



Reagents and conditions: i) TFA, CH₂Cl₂, 0 °C, 2 h; ii) azeotropic removal of water with toluene, 40 °C, 20 mmHg, 55% for **12a**, 65% for **12b**

- 13 Compound **4**: ¹H-NMR (600 MHz, CDCl₃) δ 5.56 (2H, m, H-8 and H-9), 4.76 (1H, d, *J* = 10.8 Hz, OH), 4.69 (1H, d, *J* = 5.4 Hz, H-11), 3.20 (1H, d, *J* = 10.8 Hz, H-14), 2.70 (1H, dd, *J* = 3.0, 16.8 Hz, H-7), 2.49 (1H, d, *J* = 12.8 Hz, H-12), 2.36 (1H, ddd, *J* = 1.8, 3.6, 13.8 Hz, H-4'), 2.22 (1H, ddd, *J* = 1.8, 12.8, 13.2 Hz, H-13), 2.20 (1H, m, H-4'), 2.16 (1H, m, H-5), 2.05 (1H, dd, *J* = 3.0, 13.2 Hz, H-2'), 2.03 (1H, m, H-3'), 1.99 (1H, m, H-4), 1.86 (1H, m, H-10), 1.83 (1H, m, H-2'), 1.69 (2H, m, H-4 and H-3'), 1.49 (1H, dd, *J* = 1.8, 16.8 Hz, H-7), 1.30 (1H, ddd, *J* = 1.8, 12.6, 13.2 Hz, H-10), 0.94 (3H, s, H-16), 0.88 (9H, s, *t*-BuSi), 0.20 (3H, s, MeSi), 0.15 (3H, s, MeSi); ¹³C-NMR (150 MHz, CDCl₃) δ 209.6, 125.8, 124.5, 82.9, 67.4, 60.3, 48.6, 42.2, 40.7, 40.6, 39.5, 33.6, 31.7, 29.6, 25.9, 25.8, 18.2, 15.3, -4.80, -4.90; IR (film, cm⁻¹) 3396, 2929, 1712, 1209, 788, 670, 424; HRMS calcd. for C₂₂H₃₈O₅SiNa 401.2488, found 401.2496; [*a*]_D²⁷ -3.54 (*c* = 0.427, CHCl₃).
- 14 J. Inanaga, M. Ishikawa and M. Yamaguchi, *Chem. Lett.*, 1987, 1485.